Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jerald Sklar

Dermatology Dallas, TX Medical Doctor

NPI 1821086679 CMS profile 172914

10703 Preston Rd, Dallas, TX 75230

Open in the dashboard

General payments

$36,887

1,277 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jerald Sklar of Dallas, TX is reported in the CMS Open Payments database as having received $36,887 across 1,277 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,879 228
2024 General $4,320 235
2023 General $4,782 210
2022 General $4,304 188
2021 General $3,007 151
2020 General $2,677 135
2019 General $12,918 130

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerald Sklar
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Jerald Sklar were reported at $4,879. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Jerald Sklar Dermatology median Middle half National median
2019 $12,918 $454 $129–$1,240 $163
2020 $2,677 $235 $81–$756 $114
2021 $3,007 $377 $108–$1,108 $132
2022 $4,304 $514 $143–$1,391 $149
2023 $4,782 $607 $159–$1,674 $160
2024 $4,320 $751 $204–$1,903 $164
2025 $4,879 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Almirall LLC $11,265 78 payments
  2. AbbVie, Inc. $3,386 164 payments
  3. Genzyme Corporation $2,391 90 payments
  4. Galderma Laboratories, L.P. $2,037 85 payments
  5. Regeneron Healthcare Solutions, Inc. $1,822 80 payments
  6. Novartis Pharmaceuticals Corporation $1,671 80 payments
  7. Dermavant Sciences, Inc. $1,560 61 payments
  8. Ortho Dermatologics, a division of Bausch Health US, LLC $1,378 52 payments
  9. Amgen Inc. $1,275 89 payments
  10. LEO Pharma Inc. $1,224 44 payments
  11. Other $8,879 454 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $27,262 1,267 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,525 6 payments
  3. Education $100 4 payments
Products named General payments · program years 2019–2025
  1. Seysara $10,373 46 payments
  2. DUPIXENT Immunology $2,082 81 payments
  3. VTAMA $1,606 66 payments
  4. DUPIXENT Inflammation And Immunology $1,497 65 payments
  5. Otezla $1,275 89 payments
  6. SKYRIZI $1,241 66 payments
  7. TREMFYA $1,112 49 payments
  8. TALTZ $930 47 payments
  9. BOTOX $800 36 payments
  10. OPZELURA $773 38 payments
  11. Other $19,194 823 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,479

Median for Dermatology: 534

Drug cost

$296,939

Median for Dermatology: $67,151

Branded share of claims

9.3%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 38 $154,499
Otezla Apremilast Brand 13 $62,170
Dupixent Syringe Dupilumab Brand 15 $54,856
Triamcinolone Acetonide Generic 387 $4,264
Fluorouracil Generic 40 $2,566
Valacyclovir Valacyclovir Hcl Brand 52 $2,487
Mupirocin Generic 315 $2,430
Doxycycline Hyclate Generic 167 $2,410
Mometasone Furoate Generic 92 $2,273
Clobetasol Propionate Generic 47 $2,099

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$494,502

Of which drugs: $422

Medicare patients

1,956

Average age 76

Services billed

14,363

687 women, 1,269 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 42%
Ischemic heart disease 27%
Cancer 19%
Atrial fibrillation 18%
Diabetes 17%
Chronic kidney disease 17%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 113 633 $422

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
$687 — —
DUPIXENT
$539 53 —
BOTOX
$341 — —
Zoryve
$284 — —
COSENTYX
$220 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,277 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record